Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, USA.
Department of Pharmacy, University of Michigan Rogel Cancer Center, Ann Arbor, USA.
J Oncol Pharm Pract. 2021 Dec;27(8):2014-2017. doi: 10.1177/10781552211004985. Epub 2021 Mar 26.
We report the case of a patient who experienced severe neurological symptoms collectively characterized as being "frozen" following a second oxaliplatin infusion.
A 52-year-old woman with metastatic colon cancer developed severe motor slowing, delayed and incomplete grip and dorsiflexion, speech difficulty, visual impairment, leg cramping and tingling after her second infusion of oxaliplatin. She was transferred from the infusion center to the emergency room and admitted to the hospital for further evaluation. Motor, verbal, and ocular symptoms gradually resolved within 24 hours, and she was discharged home without sequela.Management and outcome: Oxaliplatin dose was subsequently lowered and infusion time increased, and she tolerated future treatments without motor, verbal, or ocular disturbance.
In this case report, we describe a rare form of neurological toxicity involving severe motor slowing, slurred speech, and blurry vision secondary to oxaliplatin.
我们报告了一例患者在第二次奥沙利铂输注后出现严重神经系统症状，这些症状共同表现为“冻结”。
一名 52 岁女性患有转移性结肠癌，在第二次奥沙利铂输注后出现严重的运动迟缓、握持和背屈延迟且不完全、言语困难、视力障碍、腿部痉挛和刺痛。她从输注中心转至急诊室，并入院接受进一步评估。运动、言语和眼部症状在 24 小时内逐渐缓解，她无后遗症出院回家。
奥沙利铂剂量随后降低，输注时间延长，她在未来的治疗中未出现运动、言语或眼部障碍。
在本病例报告中，我们描述了一种罕见的神经毒性形式，涉及严重的运动迟缓、言语含糊和奥沙利铂引起的视力模糊。
